Table 2 Participant demographic and clinical data.
From: Neutralizing antibodies to SARS-CoV-2 variants of concern: a pediatric surveillance study
Variable | N = 619 |
|---|---|
Male sex, n (%) | 344 (56) |
Age (yrs), median (IQR) | 7 (6–9) |
Age group, n (%) | |
5 years old | 112 (18) |
6 years old | 97 (16) |
7 years old | 108 (17) |
8 years old | 97 (16) |
9 years old | 90 (15) |
10 years old | 105 (17) |
11 years old | ≤ 10 (≤ 1) |
12 years old | ≤ 5 (≤ 1) |
Medical service, n (%) | |
Emergency | 232 (37) |
Specialty service | 174 (28) |
Haematology/Oncology | 108 (17) |
Medicine | 87 (14) |
Surgery | 18 (3) |
Comorbidities, n (%) | |
Asthma | 117 (19) |
Diabetes | 13 (2) |
Possible Immuno-compromised, n (%) | |
Leukopenia1 | 86 (14) |
Neutropenia1 | 35 (6) |
Lymphopenia1 | 165 (28) |
Active Immunotherapy | 81 (13) |
Steroid Medication | 38 (6) |
COVID-19 vaccine doses before sample collection, n (%) | |
0 doses | 335 (54) |
1 dose | 169 (27) |
2 doses | 115 (19) |
Days between 1st and 2nd dose, median (IQR) | 56 (50–56) |
